Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new window
investorenquiries@pharmaust.com+61 8 9202 6814
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Company Overview
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT
  • HOME
  • ABOUT
    • Company Overview
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT

Author Archives: PharmAust

Top 20 Shareholders October 2022

Top 20 ShareholdersBy PharmAust01/11/2022

Top_Holders_Report OCT

PharmAust doses first patient with MPL in motor neurone disease trial

News & Announcements 2022By PharmAust03/10/2022

PharmAust doses first patient with MPL in motor neurone disease trial (External link)

PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease

News & Announcements 2022By PharmAust03/10/2022

PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease (External link)

PharmAust (ASX:PAA) doses first patient in MND trial

News & Announcements 2022By PharmAust03/10/2022

PharmAust (ASX:PAA) doses first patient in MND trial (External ink)

First Patient Dosed in MND Phase 1/2 Trial

News & Announcements 2022By PharmAust03/10/2022

First Patient Dosed in MND Phase 1-2 Trial

Top 20 Shareholders

Top 20 ShareholdersBy PharmAust30/09/2022

Top_Holders_Report (1)

Notice of Annual General Meeting 2022

News & Announcements 2022By PharmAust30/09/2022

Notice of AGM 2022

PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin

News & Announcements 2022By PharmAust18/08/2022

PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin (External Link)

Update on PharmAust Canine Cancer Trials

News & Announcements 2022By PharmAust17/08/2022

Update on PharmAust Canine Cancer Trials

PharmAust’s MPL trials show doubled life expectancy for dogs with cancer

News & Announcements 2022By PharmAust17/08/2022

PharmAust’s MPL trials show doubled life expectancy for dogs with cancer (External Link)

←1
23
…45678…
91011121314151617181920212223242526272829303132333435363738394041424344454647484950
51→
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER


Facebook
Facebook
fb-share-icon
Twitter
YouTube

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
4 Sep

Great spread on Louie the Beagle in @AustVetMag Australian Veterinarian Magazine - Spring Issue

https://simplebooklet.com/theaustralianveterinarianmagazine_spring_2023_issue21

Reply on Twitter 1698509346102010223 Retweet on Twitter 1698509346102010223 2 Like on Twitter 1698509346102010223 9 Twitter 1698509346102010223
pharmaust PharmAust @pharmaust ·
2 Sep

PharmAust CEO Dr Michael Thurn spoke with @Biotech_Buzz from @StocksDownUnder and @PSR_Insights about the clinical success with our flagship drug, Monepantel (MPL)

🎥 https://youtu.be/oCfvzseRDxQ?si=iBZu_GMBIg5oSiMX

Reply on Twitter 1697769500807176530 Retweet on Twitter 1697769500807176530 2 Like on Twitter 1697769500807176530 13 Twitter 1697769500807176530
pharmaust PharmAust @pharmaust ·
29 Aug

New CEO to take the helm as PharmAust progresses clinical studies

Reply on Twitter 1696342181496443106 Retweet on Twitter 1696342181496443106 2 Like on Twitter 1696342181496443106 7 Twitter 1696342181496443106
Load More

Copyright © 2023 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top